Analysis issues

There is an effective documented system for receiving samples, identifying samples against requests for analysis, showing progress of analysis, issue of report and fate of sample. 

Figures 11.21 and 11.24 from Frearson and Haskins, Chromatography and Analysis, Issue 7, (1989) by permission of RGC Publications.

The FDA has generated a list of clinical frial analysis issues fhaf need to be addressed ... 

EWEA (European Wind Energy Assoeiation). 2005. Report large scale integration of wind energy in the European power supply analysis, issues and recommendations. EWEA, Brussels, Belgium. 

Huang S-M, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in NDA submissions study design and data analysis issues. J Clin Pharmacol 1999 39 1006-1014. 

R.E. Butcher and C.J. Nelson, Design and analysis issues in behavioral teratology testing, Neurobehav. Toxicol. Teratol. 7(6) (1985) 659. 

The book concludes with perspectives on future trends and some thoughts on the future direction of LC/MS applications in the pharmaceutical industry. New standards of analytical performance are discussed with regard to throughput and capacity. A prospective look at how higher standards of analytical performance in the pharmaceutical industry will effect relationships with academia and instrument manufacturers is featured. These sections extend the initial thesis of accelerated development to include new analysis bottlenecks and perspectives on analysis issues and industry needs. 

Similarly, absolute limits are popular with lawyers guilt or innocence is (assuming no sampling or analysis issues) more clear-cut and simple to explain. 

Peace, K. (1987). Design, monitoring, and analysis issues relative to adverse events. Drug Information Journal, 21, 21-28. 

Harmonized guidance for specific data analysis issues (i.e. corrections for incomplete field recovery, interpretation of residues present below the limit of detection, guidance for interpretation of outliers and atypical observations). 

Weiner, A.L. Developing lipid-based vehicles for peptide and protein drugs. Part I selection and analysis issues. Biopharm. 1990, 3 (3), 27-32. 

Annexure 3 Is the Certificate of Analysis issued by the supplier of the raw material, which was used in the batch document in the manufacturing documents submitted with the application, included ... 

Cook, T.D., Campbell, D.T. Quasi-experimentation design analysis issues for field settings. Houghton Mifflin, Boston (1979)... 

P. C. Boon and K. C. B. Roes, Design and analysis issues for crossover designs in phase I clinical studies. J Biopharm Stat 9 109-128 (1999). 

As seen from the above analysis, issues 1 and 2 can be easily met in a fixed-bed reactor, while issues 3 and 4 are more suitable in a back-mixed bubble column reactor. However, one reactor alone is unable to satisfy all four requirements simultaneously. 

Cook TD, Campbell DT. Quasi-Experimentation Design and Analysis Issues for Field Settings. Boston, Houghton-Mifflin, 1979. 

Allan, A.M., Blakeney, A.B., Batten, G.D. Dunn, T.S. (1999) Impact of grinder configuration on grinding rate, particle size, and trace element contamination of plant samples. CA Selects Trace Element Analysis, Issue 23, 2. 

Much of the work on lipids has continued to rely on the application of conventional high-resolution methods. Many general papers are available, tackling both sampling and analysis issues (Table 4). 

A kinetics text with a strong theoretical bent that overviews transient kinetic methods and discusses data analysis issues such as error propagation and sensitivity analysis. 

---